Innovative Bladder Cancer Therapy Produces $6 Million in Sales

ImmunityBio, Inc. today announced its financial results for the third quarter ended September 30, 2024. The company achieved a net product revenue of approximately $6 million during the three months ended September 30, 2024, surpassing net product revenue of $1 million in the prior quarter and analyst estimates.

ANKTIVA® (N-803), U.S. FDA-approved and commercially available since May 2024, is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical lives through medical reimbursement policies.

ANKTIVA is a cytokine interleukin-15 (IL-15) that plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells.

By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity, resulting in a prolonged duration of complete response.

“The U.S. launch of ANKTIVA for non-muscle-invasive bladder cancer (NMIBC) CIS continues to gain momentum, and we are pleased to see the clinical impact for patients,” said Richard Adcock, President and CEO of ImmunityBio, in a press release on November 12, 2024.

“The Centers for Medicare and Medicaid Services have issued our permanent J-code, effective January 1, 2025."

"Our submission of ANKTIVA for NMIBC CIS to the U.K.'s MHRA for potential approval demonstrates our plans for global expansion. Further, we anticipate an EU submission this quarter.”